Clinical Trial Update: Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial completed evaluating the safety and tolerability of varenicline (Chantix) in Spinocerebellar Ataxia Type 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinocerebellar Ataxia Type 3

Drugs mentioned

• CHANTIX (varenicline tartrate)

Snippet

Sponsor: University of South Florida | Conditions: Spinocerebellar Ataxia Type 3 | Phase 2 | Status: COMPLETED